Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Treatment-Naive Patients With Primary Central Nervous System Lymphoma (PCNSL): A Multicenter, Prospective, Concurrent-Control Study of Methotrexate, , Rituximab,, Sintilimab ,Pirtobrutinib Versus Investigator-Selected Standard of Care

NCT07350850 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07350850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07350850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Treatment-Naive Patients With Primary Central Nervous System Lymphoma (PCNSL): A Multicenter, Prospective, Concurrent-Control Study of Methotrexate, , Rituximab,, Sintilimab ,Pirtobrutinib Versus Investigator-Selected Standard of Care
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 25, 2025
Completion date
June 30, 2029
Enrollment
77 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pcnsl, primary central nervous system lymphoma